Gastric CancersR-GASTIMNCT07787052
R-GASTIM- Study of Gastric Cancer Operable
An observational study of Gastric Cancers, run by Centre Leon Berard at 1 site in France.
Trial summary
Clinicobiological cohort of gastric cancers operated in our institution. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric Cancers
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 30 Sep 2024to 30 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III treated with standard neoadjuvant chemotherapy, operated at Centre léon Bérard, with available tumor and lymph nodes samples
Who may be able to join
- Adult patients with histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III be treated with standard neoadjuvant chemotherapy
- Knwon response to neoadjuvant chemotherapy as per TRG criteria
- Surgery of primary tumor done at Centre Léon Bérard. Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells and collected lymp nodes
Who cannot join
- Patient refusal to participate to this clinicobiological cohort
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Centre Léon Bérard
Lyon, 69008
Clélia coutzac, MD,PhD, 0033478782828, clelia.coutzac@lyon.unicancer.fr
About this study
Official title: R-GASTIM - Clinicobiological Cohort of Gastric Cancers
Clinicobiological cohort of gastric cancers operated in our institution.
Read the detailed description
Study of microenvironment of gastric cancers using tumor and lymph nodes, collected as per standard of care. Analysis by RNASeq and HyperIon
- Conditions
- Gastric Cancers
- Keywords
- gastric cancer, microenvironment, neoadjuvant chemotherapy
- Medical subject headings
- Stomach Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Gene expression
Transcriptom of Surgery and lymp node specimen
Measured: surgery
Secondary outcomes (1)
HyperIon
Hyperion data on surgery and lymph nodes sample
Measured: surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2026
- Study start30 Sep 2024
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancersStudies of the same condition, open and under way.
- More trials run by Centre Leon BerardThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Leon Berard
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07787052
- Sponsor's protocol ID
- R201-004-117
- Other IDs
- R201-004-117
- Acronym
- R-GASTIM
- Status last verified
- Aug 2026
- First submitted
- 30 Sep 2024
- Last updated
- 26 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- R-GASTIM - Clinicobiological Cohort of Gastric Cancers
- ClinicalTrials.gov ID
- NCT07787052
- Acronym / sponsor ID
- R-GASTIM / R201-004-117
- Conditions
- Gastric Cancers
- Keywords
- gastric cancer, microenvironment, neoadjuvant chemotherapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Centre Leon BerardUniversity, hospital or other
- Study start
- 30 Sep 2024 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 26 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinicobiological cohort of gastric cancers operated in our institution.
Detailed description
Study of microenvironment of gastric cancers using tumor and lymph nodes, collected as per standard of care. Analysis by RNASeq and HyperIon
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III treated with standard neoadjuvant chemotherapy, operated at Centre léon Bérard, with available tumor and lymph nodes samples
Key inclusion criteria (3 listed)
- Adult patients with histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III be treated with standard neoadjuvant chemotherapy
- Knwon response to neoadjuvant chemotherapy as per TRG criteria
- Surgery of primary tumor done at Centre Léon Bérard. Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells and collected lymp nodes
Key exclusion criteria (1 listed)
- Patient refusal to participate to this clinicobiological cohort
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Gene expression
Time frame: surgery
Transcriptom of Surgery and lymp node specimen
1 secondary outcome
HyperIon
Time frame: surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancers, run by Centre Leon Berard at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clelia Coutzac, MD,PhD (0033478782828, clelia.coutzac@lyon.unicancer.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gene expression (time frame: surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.